高盛-劲方医药(2595.HK):WCLC26会议展示强化GFH375二线及以上非小细胞肺癌疗效,10月聚焦ESMOVSTM更新-GenFleet Therapeutics(2595.HK):WCLC26 presentation strengthened GFH375 in 2L+ NSCLC;ESMO VSTM update as focus in Oc-20260914【7页】

发表回复

后才能评论